Bioventix (BVXP) Full Year results June 2016 interview
Length: c 20 mins
Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange.
He goes on to talk about the NT proBNP licence, which comes to an end July 2017, with all revenue (c.£750k) being lost from August 2017 onwards. Peter is confident Troponin, will launch at some point in 2017, based on all the updates given by Siemens, although timing is in Siemen’s hand. He has estimated July 2017 to start roll-out, it being the mid point of the year. He mentions the initial and on-going revenue expectations for Troponin.
Peter briefly discusses other antibodies already producing revenue, and future developments for the medium term. Cardinor, Norway is not discussed, since this is unlikely to result in revenues over the near term.
Peter answers questions on a few potential threats, including consolidation of customers and any new technologies that could disrupt their market.
Finally, he talks about staff motivation, and financial reward.
Videos from Bioventix